Structure of the human galanin receptor 2 bound to galanin and Gq reveals the basis of ligand specificity and how binding affects the G-protein interface

PLoS Biol. 2022 Aug 1;20(8):e3001714. doi: 10.1371/journal.pbio.3001714. eCollection 2022 Aug.

Abstract

Galanin is a neuropeptide expressed in the central and peripheral nervous systems, where it regulates various processes including neuroendocrine release, cognition, and nerve regeneration. Three G-protein coupled receptors (GPCRs) for galanin have been discovered, which is the focus of efforts to treat diseases including Alzheimer's disease, anxiety, and addiction. To understand the basis of the ligand preferences of the receptors and to assist structure-based drug design, we used cryo-electron microscopy (cryo-EM) to solve the molecular structure of GALR2 bound to galanin and a cognate heterotrimeric G-protein, providing a molecular view of the neuropeptide binding site. Mutant proteins were assayed to help reveal the basis of ligand specificity, and structural comparison between the activated GALR2 and inactive hβ2AR was used to relate galanin binding to the movements of transmembrane (TM) helices and the G-protein interface.

MeSH terms

  • Cryoelectron Microscopy
  • Galanin / chemistry*
  • Galanin / metabolism
  • Heterotrimeric GTP-Binding Proteins* / metabolism
  • Humans
  • Ligands
  • Receptor, Galanin, Type 2 / chemistry*
  • Receptor, Galanin, Type 2 / metabolism

Substances

  • Ligands
  • Receptor, Galanin, Type 2
  • Galanin
  • Heterotrimeric GTP-Binding Proteins

Grants and funding

This work was supported by Japan Agency for Medical Research and Development, AMED under grant numbers JP21fk0310103 (S.-Y.P.), JP20ae0101047 (K.M.), and by JSPS/MEXT KAKENHI grant (JP19H05779, 21H02449 to S.-Y.P.), (JP20H05873 (K.M.)). This work was also supported by a grant (NRF-2020M3A9G7103934 to W.L.) from National Research Foundation (NRF) of Korea. A.I. was funded by KAKENHI 21H04791 and 21H05113 from the Japan Society for the Promotion of Science (JSPS); the LEAP JP20gm0010004 and the BINDS JP20am0101095 from the Japan Agency for Medical Research and Development (AMED). K.M. was funded by the BINDS JP20am0101093 from AMED. A.I. was funded by FOREST Program JPMJFR215T and JST Moonshot Research and Development Program JPMJMS2023 from the Japan Science and Technology Agency (JST); Daiichi Sankyo Foundation of Life Science; Takeda Science Foundation; The Uehara Memorial Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.